The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.
 
Geoffrey Johnson
Leadership - Green Clinic (I); Nucleus RadioPharma (Inst)
Stock and Other Ownership Interests - Perspective Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); Curium Pharma (Inst); MedTrace (Inst); MorphImmune (Inst); Novartis (Inst); Siemens Healthineers (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst); Z-Alpha (Inst)
Research Funding - Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); MedTrace (Inst); Novartis (Inst); Pfizer (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Patents on Radiopharmaceuticals; Patents on Radiopharmaceuticals (Inst)
 
Eva Lengyelova
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Luke Nordquist
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Fusion Pharmaceuticals
 
Vikas Prasad
Consulting or Advisory Role - Bayer HealthCare Pharmacuticals; Cellectar; Curium Pharma; Lantheus Medical Imaging; Lilly; Telix Pharmaceuticals
Speakers' Bureau - Curium Pharma
Travel, Accommodations, Expenses - RayzeBio; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ECOG-ACRIN; ENETS; ESMO; ICPO Foundation; SNMMI
 
Hong Song
Consulting or Advisory Role - Lanth; Lanth
Research Funding - Clarity Pharmaceuticals (Inst)
 
Monique Anderson
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Othon Gervasio
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Robert Miller
Employment - Clarity Pharmaceuticals; Scancell Ltd.
Consulting or Advisory Role - Clarity Pharmaceuticals; Scancell Ltd.
Travel, Accommodations, Expenses - Clarity Pharmaceuticals; Scancell Ltd.
 
Alton Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; ARTbio; BioNTech SE; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Lilly; Perspective; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Actinium Pharmaceuticals; Advancell; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Intellisphere; Lantheus Medical Imaging; Pfizer; Point Therapeutics; Ratiopharm; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals; Advancell; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bayer; Clarity Pharmaceuticals; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Lantheus Medical Imaging; Novartis; Pfizer; Point Biopharma; Ratiopharm; Sanofi; Telix Pharmaceuticals; Telix Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Novartis (Inst); POINT Biopharma (Inst); Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - Bayer; Lantheus Medical Imaging; Sanofi
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics